HC Wainwright Issues Positive Forecast for OVID Earnings

Ovid Therapeutics (NASDAQ:OVID) – Equities research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for Ovid Therapeutics in a research note issued on Thursday, April 9th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.09). HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Ovid Therapeutics’ FY2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.34) EPS.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings data on Wednesday, March 18th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.16. Ovid Therapeutics had a negative return on equity of 23.98% and a negative net margin of 240.11%.The business had revenue of $0.72 million for the quarter, compared to the consensus estimate of $0.06 million.

Several other equities analysts also recently commented on OVID. Lifesci Capital began coverage on Ovid Therapeutics in a research note on Monday, December 22nd. They issued an “outperform” rating and a $4.00 price objective on the stock. Wall Street Zen upgraded Ovid Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Wedbush boosted their target price on shares of Ovid Therapeutics from $5.00 to $7.00 and gave the company an “outperform” rating in a report on Friday, March 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Ovid Therapeutics in a research report on Thursday, January 22nd. Finally, BTIG Research restated a “buy” rating and set a $4.00 target price on shares of Ovid Therapeutics in a research report on Thursday, March 26th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $4.63.

Ovid Therapeutics Price Performance

Ovid Therapeutics stock opened at $2.75 on Monday. Ovid Therapeutics has a 12 month low of $0.25 and a 12 month high of $3.11. The company has a current ratio of 8.97, a quick ratio of 8.97 and a debt-to-equity ratio of 0.09. The business’s 50 day simple moving average is $1.94 and its 200 day simple moving average is $1.70. The company has a market cap of $362.67 million, a price-to-earnings ratio of -8.87 and a beta of -0.03.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Benin Management CORP bought a new position in shares of Ovid Therapeutics in the fourth quarter worth $31,000. Private Advisor Group LLC bought a new position in shares of Ovid Therapeutics in the third quarter worth $33,000. Apollon Wealth Management LLC bought a new position in shares of Ovid Therapeutics in the third quarter worth $36,000. Total Clarity Wealth Management Inc. bought a new position in shares of Ovid Therapeutics in the fourth quarter worth $47,000. Finally, LPL Financial LLC increased its holdings in shares of Ovid Therapeutics by 150.0% in the fourth quarter. LPL Financial LLC now owns 30,000 shares of the company’s stock worth $49,000 after purchasing an additional 18,000 shares during the period. Institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.